|Subject||KIST Transfers Nanocage Technology to Samyang Biopharmaceuticals (2018.01.16)|
KIST Transfers Nanocage Technology to Samyang Biopharmaceuticals
- KIST’s medicinal nano technology selectively attacks cancer cells
- Samyang Biopharmaceuticals is a leading developer of nanocage technology-based treatments
On January 16, the Korea Institute of Science and Technology (KIST) and Samyang Biopharmaceuticals signed a technology transfer agreement regarding newly developed nanocage technology and its potential applications. A down payment of KRW 500 million was agreed upon, with a licensing fee of 3%.
The team that developed this new technology was led by Dr. Kim In-San of KIST’s Center for Theragnosis. Their antitumor immunity particles not only seek out and destroy cancer cells but also jumpstart the body’s immune system, theoretically deterring cancer cells from recurring or even growing in the first place.
These days, countries around the world are actively conducting R&D on antitumor immunity, and the market potential for this research is seemingly great. In fact, the antitumor immunity market, whose size was about USD 1.4 billion in 2014, is expected to reach as high as USD 27.6 billion by 2020.
Samyang Biopharmaceuticals’ research currently focuses on DDS-based anticancer drugs, biologics-related pharmaceutical fields, and absorbable material-based medical devices (MD). Because of its technological expertise in pharmaceutics and MD, the company is potentially ripe for overseas expansion.
As part of this technology transfer, KIST and Samyang Biopharmaceuticals will work together to verify the usefulness of this new technology before developing new forms of treatment through clinical trials.
Samyang Biopharmaceuticals’ president, Mr. Eom Tae-Ung, said, “Samyang Biopharmaceuticals has been engaging in open innovation through active cooperation with other organizations, and the technology transferred by KIST will accelerate our R&D into biologics-related pharmaceutical fields.”
|Previous||Dr. Kim Soo Hyun Takes Over as President of the Korean Tissue Engineering and Regenerative Medicine Society (2018.01.17)|
|Next||Dr. Cho Won Il Takes Over as President of the Korean Electrochemical Society (2018.01.10)|